Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

itionally, the study met the following secondary endpoints: a responder analysis of improvement in pain intensity (p<0.025), a responder analysis of improvement in pain relief (p<0.01), improvement in patient sleep scores (p=0.028) and overall patient global satisfaction (p=0.04). This study also found that significant neuropathic pain relief was achieved at a small fraction of the plasma levels observed after systemic dosing. The cream was found to be safe and well tolerated across all age groups studied.

"These findings add to a growing body of clinical data which demonstrate the potential for NP-1 to provide effective, additive, long-term relief to the 15 million Americans who suffer from the pain of peripheral neuropathies. The outcome from the pharmacokinetic trial in particular supports the safety of NP-1 topical cream and even more importantly its ability to be added to orally administered therapies," remarked Jack Talley, President and CEO of EpiCept. "We believe NP-1 has the largest market potential of any of our pain product candidates and we are focused on advancing it through its current Phase IIb trials. These trials are progressing as expected and we remain on track to be able to share preliminary results from the first trial by the fourth quarter of 2007.

"Current systemically-delivered analgesics have well documented limitations and significant potential side effects. The local mechanism of action of NP-1 demonstrated in these studies could reduce these side effects by blocking pain directly at its source," remarked Stephane Allard, MD, Chief Medical Officer.

EpiCept NP-1 is currently undergoing two Phase IIb trials, enrolling a total of 700 patients. The first trial is a 200 patient, placebo-controlled study of NP-1 in patients with diabetic peripheral neuropathy (DPN). More patients suffer from DPN than any other type of neuropathic pain. Only two medications are currently approved for this use. The trial is intended to confirm
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:5/17/2013)... May 17, 2013  Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...
(Date:5/17/2013)... , May 17, 2013 ... developer of oral drug delivery systems, announced today that ... cleared the Company,s Investigational New Drug application(IND) for ORMD-0801, ... pleased to have the FDA clearance to proceed," stated ... "The upcoming trial is a major milestone for Oramed ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... March 16 Healthpoint today announced that it has ... of HP802-247 in venous leg ulcers. HP802-247 is a ... is designed to determine the effectiveness of two cell ... with standard care, compared to placebo plus standard care, ...
... Aims To Enhance Precision and Reduce High Failure ... Hamilton, N.J., March 16 ICON (Nasdaq: ... outsourced development services to the pharmaceutical, biotechnology and ... in centralized psychiatric patient evaluation, today announced that ...
Cached Medicine Technology:Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3ICON and MedAvante Sign Alliance Agreement 2
(Date:5/18/2013)... May 18, 2013 The “World Healthcare ... and studies the major market drivers, restraints, and opportunities ... world. , Browse , 89 ... in-depth TOC on "Healthcare IT Market" , ... customization on reports. , The global healthcare IT market ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 During Better ... loss should consider the legal protections they have, including ... problems arise with their child’s treatment or hearing aid ... Since 1927, the American Speech-Language-Hearing Association has used the ... and to promote treatment, such as cochlear implants, which ...
(Date:5/18/2013)... 2013 Adolescents, especially young males, who ... or “K2” are landing in emergency rooms across America. ... drug epidemic with a new treatment program for ... to research from the National Institute on Drug Abuse, ... among American teenagers. In 2012, 11 percent of high ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The ... Gov. John A. Kitzhaber, M.D., (D) to sign a ... by prohibiting minors under the age of 18 from ... become the third state in the nation to enact ... enacted similar indoor tanning bans for minors. Nationwide, 34 ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The topics that ... are scrum framework, scrum roles, scrum meetings, scrum artifacts, and ... (8 PDUs) for attending them. , These trainings are suitable ... is also ideal for those who will be a part ... those who want to explore Agile and Scrum, but are ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3
... six major factors that affect how happy a woman ... been uncovered. Researchers writing in the open access journal ... well as final breast appearance, there are five other ... from Memorial Sloan-Kettering Cancer Center, New York, led a ...
... for Procrit, Aranesp, experts say, , , THURSDAY, April 30 ... that drugs such as Procrit and Aranesp, often used ... the risk of death and serious adverse events such ... (ESAs), have also been associated in prior studies with ...
... HOUSTON, April 30 As an expectant mother, her first official ... delivery arrives. Here are four unique ideas to make this ... women prescribed bed rest, this can be a vexing time. ... babies) to stay off her feet, but she is still very ...
... , April 30 ... biopharmaceutical company focused on in-licensing, developing and commercializing proprietary ... today announced that it will release its first quarter ... closes on Thursday, May 7, 2009. Cadence management will ...
... to treat Type 2 diabetes may have unintended effects on the ... some patients and a greater risk of pancreatic cancer in long-term ... In a study published in the online edition of the journal ... Center at UCLA found that sitagliptin, sold in pill form as ...
... Thoratec Corporation (Nasdaq: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal 2009 on Thursday, May 7.The company ... results and operating activities open to all interested parties ...
Cached Medicine News:Health News:What influences women's opinions on their breast surgery? 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 3Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 4Health News:Four Unique Gifts for Expectant Moms Includes New Technology That Enhances Pre-Natal Bonding 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 3Health News:Thoratec Schedules First Quarter Conference Call, Webcast 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,409-7) or contact custom...
... samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, ... Volume Range (ul) ... 1.0~1.5 Imprecision(%) ... 10 ...
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Medicine Products: